SLC3A2

Across TCGA pan-cancer cohorts, SLC3A2 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated SLC3A2 data layer compared with 27 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher SLC3A2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC3A2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

CHOL, KIRP, and HNSC are the cancer types where SLC3A2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	DFS	Median	All	0.100	0.496	.006	21	view →
KIRP	DFS	Median	All	0.426	0.871	<.001	12	view →
HNSC	DFS	Median	III,IV	0.157	0.596	.005	12	view →
STAD	OS	Median	IV	0.001	0.544	<.001	12	view →
SKCM	OS	Median	III,IV	0.230	0.721	.004	9	view →
LUAD	OS	Median	II,III,IV	0.090	0.677	<.001	6	view →
UCEC	DFS	Median	II,III,IV	0.859	0.437	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

SLC3A2–CHOL (DFS)

Open the CHOL breakdown →